Detalhe da pesquisa
1.
Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases.
Bioorg Med Chem Lett
; 22(1): 262-6, 2012 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22153662
2.
Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.
Bioorg Med Chem Lett
; 22(9): 3050-5, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22497760
3.
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
J Med Chem
; 49(22): 6465-88, 2006 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-17064066
4.
Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators.
J Med Chem
; 58(8): 3522-33, 2015 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-25790336
5.
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.
J Med Chem
; 47(4): 871-87, 2004 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-14761189
6.
Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
J Med Chem
; 45(6): 1300-12, 2002 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-11881999
7.
Correction to Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators.
J Med Chem
; 59(7): 3576, 2016 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27003331
8.
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Mol Oncol
; 3(3): 248-61, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19393585